Mission Statement KREBS is committed to:
* be the world-class, research-driven manufacturer of
Biopharmaceuticals, Intermediaries, Agro industrial products to produce
latest and Quality Products.
* add Ethical Value to the Business Practices and conduct business with
* serve Customers, Shareholders and Society at large.
* operate in a Safe and Echo - Friendly atmosphere.
* conduct research constantly seeking innovations.
The overall philosophy of the Company is to be an ideal and model
Corporate Citizen and hence takes on itself to carry out its business
by following good corporate practices like
* Good Corporate Governance
* Transparency and Honesty
* Social Responsibility
* Responsibility towards
d) Suppliers and
e) Society at large
About the Company
Krebs Biochemicals & Industries Limited (KBIL) was incorporated in the
year 1991 as a Public Limited Company with the main objective of
establishing commercially viable biotech processes with applications in
Medicine, Agriculture and Industry. The company has pioneered in the
fermentation technology over the last decade.
KBIL went into public in the year March 1994 to part finance its
fermentation technology project. KBIL has a strong shareholding
community of over 10000 spread across all parts of the country.
Presently the equity shares are listed on HSE, BSE and NSE with active
trading on BSE.
KBIL has manufacturing facilities at Ragadichelika, Nellore (Unit I)
and at Kothapalli Village, Kasimkota Mandal, Visakhapatnam District
(Unit II). Products manufactured from Unit I.facility are Ephedrine,
Pseudoephedrine and their salts, which are used for making formulations
for respiratory ailments, viz., cough, cold etc.
The facility at Unit II is being used to manufacture a basket of
fermentation products viz., Lovastatin, Simvastatin, (all cholesterol
reducing agents) and Vitamin-C and its salts (neutraceuticals), which
has wider applications in Pharma, feeds, foods beverages etc. The
company is focussing on the research and development of new bio
molecules and genetically engineered products by synthetic and
The R&D centres of KBIL situated at Unit I and ICICI Knowledge Park,
Hyderabad are recognized by DSIR, New Delhi. The growth of KBIL is
strengthened by its work force consisting of Doctorates, Post
Graduates, Technocrats etc.,
KBIL has received ISO 9002 Certification for its
Unit-I situated at Nellore from Yarsley International Certifications
Services accredited by United Kingdom Accreditation Services (U.K.A.S.)
in the year 2001. Unit I is also accredited with European Certificate
of Suitability from European Directorate for the Quality of Medicines
(EDQM). Further, Certificate of Suitability has been submitted to EDQM
for Lovastatin and Simvastatin.
The Unit I is a USFDA certified facility. Unit II is in the process of
obtaining USFDA. The requirement of various criteria by USFDA involving
appropriate designs, data collection, statistics and safety monitoring
in concurrence with Good Manufacturing Practices and Good Laboratory
Practices are followed by KBIL.
KBILs past performance and success holds the strength for opening up
new avenues for diversification/in addition to the existing line of
bulk drugs. The company follows current Good Manufacturing Practices
(cGMP) in addition to Good Business Practices.
Under the diversification programme and as a part of seeking new
opportunities, KBIL has set up stackable potato chips plant at
Gaganpahad, Hyderabad. Further, KBIL has acquired The Nannapaneni
Venkat Rao Co-operative Sugar Factory, Jampani under the privatisation
process and successfully completed crushing operations for the season
KBIL focuses on knowledge and expertise which will involve both
experience and manpower skills necessary to organize suitable plant
infrastructure at low cost for enabling the fermentation activities as
an integral part of exploiting traditional microbial technology.